Adicet Bio, Inc. — Form 8-K
Filed September 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Adicet Bio announced completion of the last patient visit for its Phase 1 prula-cel trial in 22 SLE/lupus nephritis patients (13 with ≥12 months follow-up), with topline results expected September 2026. The company also received FDA IND clearance for ADI-212 (mCRPC) with Phase 1 enrollment planned for 4Q 2026, and is advancing an in vivo CAR-T platform with first clinical candidate expected 2H 2027. No specific financial figures, deal amounts, or shareholder changes were disclosed.
Why this rating
Clinical milestone de-risks prula-cel but data not yet released; ADI-212 IND clearance validates approach. Moderate materiality for $50.5M biotech: pipeline progress supports long-term value, but pre-revenue company remains speculative until efficacy proven.
See more from September 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.